TAIPEI, Aug. 6, 2013 /PRNewswire/ -- TTY BIOPHARM was awarded "Outstanding Company of the Year", the highest award given at the Bio Taiwan 2013 Exhibition. At the opening ceremony on July 18, Rong-Jing Lin, Chairman and General Manager of TTY BIOPHARM, received the prize from Ma Ying-jeou, President of Taiwan.

Bio Taiwan 2013, held at Taipei World Trade Center's Nangang Exhibition Hall on July 18-21, featured 520 companies in biotech, pharmaceutical, healthcare and equipment and raw material sectors from around the world. Combining exhibitions, conferences, luncheons, symposia and BioBusiness Asia for the first time, the event attracted international professionals from Germany, Switzerland, the US, Canada, Singapore, Japan, Australia, South Korea, India and Israel.

TTY BIOPHARM stood out for its remarkable operating results, stable and rapid growth, as well as outstanding performance in R&D and its contributions to industry growth, evidenced by the 61 overseas drug licenses and 46 patents the company has obtained to date. During the last decade, TTY BIOPHARM has been aggressively seeking expansion and looking for international partners. The company has demonstrated much higher growth potential than its competitors, while maintaining focus on new drug research and technology innovation and deepening its reach into the oncology sector. This was one of the key factors for which the firm has received high recognition from the judging panel as a role model for the biotech industry.

TOT BIOPHARM, an affiliate company of TTY BIOPHARM, was established in Suzhou Industrial Park in 2010 and is a biopharmaceutical firm specializing in the research and development, manufacturing and international marketing of new drugs. TOT BIOPHARM is committed to combining the R&D strengths of both mainland China and Taiwan to become a global drug leader. TOT BIOPHARM plans to invest more than US$100 million in stages to expand its factory complex in Suzhou Industrial Park. Its core drugs include:

1. Specialty drugs: In-depth development and application of high barrier formulations such as liposome technology
2. Biological drugs: Development of therapeutic monoclonal antibodies, both biosimilars and new biologic entities
3. Innovative therapeutics: Development of innovative therapeutics including viral and non-viral gene therapy, and immunotherapy drugs

TOT BIOPHARM is committed to building on its local strengths and development. Following on completion of construction of phase one of its factory complex in Suzhou Industrial Park in November 2012, TOT BIOPHARM views the mainland as its base for R&D, manufacturing and marketing of new anti-tumor drugs and strives to build a clinical trial platform in Asia. The firm plans to start construction of phase two of its facilities in Suzhou Industrial Park soon. In addition, TOT BIOPHARM plans to continue to expand its operations center with a focus on global competitiveness and intentions of cooperating with global innovative biomedical firms, sparing no effort in its contribution to the development of drugs for tumors, the growth rates of which have been rapidly increasing among the populations of greater China.

SOURCE TOT Biopharm Company Limited